Mind Matters ECHO

Module: Substance Use

Session 1: Engaging Patients and Families in Destigmatized Substance Use Care

November 9, 2022



Mount Sinai Health Partners

Welcome!

- Pre-survey: bit.ly/sudmeeting1
- Hub team introductions
- Disclosures
- Questions during presentations



Case Presentation



Annelisse Guillen, LMSW Internal Medicine Associates

Patient Information

Demographic Information	 54 year old cis male Dual eligible (Medicare and Medicaid) Some college Not currently employed Lives alone SSI, Food stamps, and Medicaid
Medical History	 Elevated PSA Dysuria Repetitive UTIs Acute Cystitis Attends urology visits at Mount Sinai Union Square
Current Psychiatric Diagnoses	Paranoid schizophreniaAnxiety
Current Treatment Plan	 Patient attends group therapy, individual therapy and has medication management at Mount Sinai Hospital Adult Outpatient Psychiatry Clinic: 5th Avenue



Patient Information

Current Medications	 Risperdal Consta 50 mg Docusate sodium 100mg Senokot 8.6 mg Klonopin 0.5 mg Clozaril 100 mg Maalox BactriumDS Ditropan
Previous Psychiatric Hospitalization	 5/17-5/26/21 at NYP Westchester for +PI, involuntary 2/17/21-3/3/21 at Metropolitan for paranoia and anxiety, voluntary Hx of heavy ER utilization for anxiety/panic 8/17/17-8/28/17 at MSH for anxiety/panic Hx of hospitalizations in the 1990s, first 1993 for psychosis/stalking, no hx of state hospitalizations
History of Trauma	 Brother assaulted him in the past and had order of protection against him No longer has one because hasn't had issues in several years



Patient Information

Symptoms of Depression	• None
Symptoms of Anxiety/Panic	 Chest pain Shortness of breath Constant worry Symptoms occur suddenly and last until he arrives at the ED
Suicidality	• None
Areas of Support and Consultation Being Sought	 Identify appropriate psychosocial referrals Strategies for engaging the patient and/or their caregivers/family
Main Question	 Strategies for engaging with patient and reducing ED visits



Engaging Patients and Families in Destigmatized Substance Use Care

Mind Matters ECHO November 9, 2022

Prameet Singh, MD Associate Professor, Psychiatry VP Behavioral Health, MSHS



Didactic Presentation



Prameet Singh, MD

Vice President, Behavioral Health Mount Sinai Health System Associate Professor of Psychiatry Icahn School of Medicine at Mount Sinai

Learning objectives

- ► Understand the complexities of substance use as they present in clinical practice
- ► Learn strategies to assess the presence and severity of SUDs
- Develop effective strategies for engagement and collaboration with patients and families referred to or participating in substance use care

In other words....

- ► What is the prevalence?
- ► How to recognize and diagnose the disorder
- ► What to do once it's diagnosed
- ► How to treat patients once referred and engaged in treatment

Definitions

- ▶ ____ Use Disorder: DSM-5
- Induced Disorders
 - Mania
 - Cognitive
 - Delirium
 - -Sleep
 - -Sexual Dysfunction
 - Psychotic
 - Depressive
 - Obsessive-Compulsive
 - -Anxiety

Consequences in four domains

- Physical dependence
 - Withdrawal
 - Tolerance
 - Cravings and urges to use
- ► Risky use
 - Use in hazardous situations
- Social problems
 - Spending most time obtaining, using, or recovering from
 - Impaired work, interpersonal, or school
 - Continued use despite relationship problems
 - Giving up social, occupational, or recreational activities
- Impaired control
 - Taking larger amounts or duration than intended
 - Use despite medical consequences
 - Unsuccessful efforts to cut down

Severity measure

The DSM-5 allows clinicians to specify the severity of the SUD based on the number of symptoms

Severity classification	Number of identified symptoms
Mild	2-3
Moderate	4-5
Severe	6 or more

10 categories of substances

- Alcohol
- ► Caffeine
- Cannabis
- ► Hallucinogens
- Inhalants
- Opioids
- Sedatives
- ► Hypnotics, or anxiolytics
- Stimulants (including amphetamines, cocaine, and other stimulants)
- ► Tobacco

Prevalence of Alcohol Use Disorder (AUD)

- ► Lifetime Prevalence AUD 29%
- ▶ 12 month prevalence AUD 14%
- Only 20% are treated over lifetime

Prevalence of Drug Use Disorder (DUD)

- ► Lifetime Prevalence DUD is 10%
- ▶ 12 month prevalence DUD is 4%
- ► Only 26% of those with lifetime prevalence are treated

Mental illness and substance use disorders in the US in 2020 among adults

PAST YEAR, 2020 NSDUH, 18+



Barriers to treatment

- ► Lack of recognition
- Lack of reporting/acknowledgement
- ► Most never present to BH clinics
- Emergency rooms see people in a med-surg crisis and the emphasis is not on the SUD
- ► Few volunteer the information at their primary care visit

Barriers to recognition at medical visit

- ► Lack of time
- Stigma and judgment
- Provider lack of information regarding treatment options
- Skepticism about treatment effectiveness
- Lack of treatment options
- Complicated insurance/TPP issues
- Patient denial of problem or services
- Patient refusal of referral

Goals of enquiry

- Assess presence of SUD
- Assess stage of change
- ► Strengthen alliance
- ► Look for a collaborator in patient and family
- Provide options
- ► Leave the door open

Making the enquiry

- Start off with the right expectations
- ► Set a non judgmental tone
- ► Reinforce confidentiality

Tips to improve validity

- Reduce the shame/guilt associated with a positive response
- Make gentle assumptions
- Provide a range of expectations
- ► Make specific enquiries
- ► Find conversational opportunities to use the aforementioned strategies

Stages of change

- ► Pre-contemplation
- ► Contemplation
- ► Planning
- ► Action
- Relapse prevention/maintenance

Levels of care

- Detox: Short-term admission to manage withdrawal syndromes
- Rehab: 14-28 days to start behavioral change, enhance motivation and jump-start recovery
- Outpatient rehab and intensive outpatient treatment (IOP): 3-12 months
- MAT: medication-assisted treatment

Opioid (methadone) treatment programs

- Uniquely regulated
- ► Useful for a niche patient
- ► Buprenorphine is a far better option for most

ASAM CONTINUUM OF CARE





Source: <u>American Society of</u> Addiction Medicine

Self-help modalities

- ► AA/NA and other 12 step groups
- ► Al-Anon
- ► SMART recovery: Self Management and Recovery Training

Level of care determination

- ► Consider 6 domains
 - -Acute intoxication or withdrawal potential
 - -Biomedical conditions and complications
 - Emotional/behavioral/cognitive conditions
 - Readiness to change
 - Relapse potential
 - Recovery environment

Summary

- ► Be aware of the prevalence
- Avoid stereotyping in either direction
- ► Set the stage for openness and transparency
- Collaborate rather than direct
- ► Learn about the options that exist
- Assess stage of change and match accordingly



ANY QUESTIONS?

THANK YOU!